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Abstract The strategy for the follow-up of soft tissue sar-
comas (STS) after therapy is tailored to the individual risk 
of recurrence and based on efficient rather than sophis-
ticated methods of observation. Along with advances 
in the treatment of sarcomas, earlier detection of a less 
advanced and resectable recurrent disease (local or 
metastasis—especially to the lungs) can prolong patient 
survival. Since the majority of STS relapses occur within 
5 years after treatment (approximately 80 % of metastases 
to the lung and close to 70 % of local recurrences within 
the first 2–3 years), in the period between 2 and 3 years 
after treatment, it is mandatory to follow-up patients 
every 3 months and perform careful history and physi-
cal examination (especially scars after surgery of the pri-
mary site) and a chest X-ray. There is no reason to per-
form other studies in asymptomatic patients (unless the 
patient reports symptoms). In case of retroperitoneal or 
intraperitoneal STS (including gastrointestinal stromal 
tumor), contrast-enhanced computed tomography of the 
abdomen and pelvis is recommended as the follow-up 
modality of choice. In this paper we outline the current 
recommendations for the follow-up strategy.
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Pattern of recurrence in soft tissue sarcomas 
(STS)
It is estimated that after treatment of primary STS the 
disease recurs in approximately 40–60 % of patients [1–4], 
depending on histological grade and subtype of sarcoma, 
tumor size, and type of local treatment. The majority of 
recurrences (approximately 80 %) occur within the first 
3 years of observation. The site of recurrence is highly 
dependent on the location of the primary tumor. The 
most common localization of STS is the lower extrem-
ity and these tumors mainly spread to the lungs (being 
the site of first recurrence). Local recurrences are rare, 
especially when treatment follows the clinical practice 
guideline (multidisciplinary approach). There are also 
rare subtypes of limb and trunk STS with a propensity for 
metastatic spread to the lymph nodes (rhabdomyosar-
coma, epithelioid sarcoma, clear cell sarcoma, or synovial 
sarcoma) and intrabdominally (myxoid liposarcoma). In 
retroperitoneal (the most common being liposarcoma) 
or visceral (e.g., gastrointestinal stromal tumors—GIST) 
STS, the most frequently observed recurrences are local 
or intraperitoneal relapse (especially GIST), followed by 
liver metastases.
Benefits of follow-up
Recurrence of the disease, particularly metastases to 
distant organs (e.g., lungs, liver) determines sarcoma 
patient survival. Approximately 50 % of patients with 
high grade STS die of metastases. There is evidence that 
in recurrent sarcoma, radical multimodal recurrent 
tumor/metastasis therapy can provide long-term patient 
survival. As mentioned above, metastases to the lung are 
the most frequent single location of disease recurrence in 
patients with extremity STS (> 70 %). It was confirmed in 
several series of patients that the radical excision of lung 
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metastases yields significantly longer overall survival 
compared with patients with inoperable disease. Hence, 
early detection of disease relapse (at the stage of count-
able and resectable metastases) may give patients the 
chance of longer survival [5–7].
Regular H&P (history and physical examination) with 
a chest X-ray permit detection of more than half of cases 
with asymptomatic lung metastases [1, 4, 7]. It is also 
estimated that lung metastasectomies enable long-term 
survival in 30–40 % of cases [6, 8, 9]. Moreover, publica-
tions by Roswell Park Cancer Institute [10, 11] indicate 
that long-term survival in sarcoma patients with metas-
tases to the lungs was achieved only by surgical treat-
ment of clinically asymptomatic, countable metastases 
to the lungs, which is why radiological assessment of 
the chest during follow-up is of great importance. Other 
studies indicate that the lower number of lung metas-
tases leads to better treatment results, suggesting the 
importance of earlier detection of sarcoma recurrence 
during follow-up. According to the literature analyzing 
regular follow-up after therapy of primary STS, regular 
chest X-rays can detect more than 60 % of lung metas-
tases in the early stages in asymptomatic patients. This 
means that chest X-ray is sufficient for routine follow-
up. Detection of the presence or suspected presence of 
a nodule on chest X-ray is an indication for computed 
tomography (CT). The CT helps to assess the num-
ber and location of nodules in the lungs, invasion of 
the mediastinum and pleura, as well as spread to hilar 
and mediastinal lymph nodes. For the routine follow-
up, there is no need for CT of the chest, because it has 
a lower specificity than chest X-rays. The chest CT scan 
should only be considered in very high risk STSs, and in 
patients after metastasectomy. In 2002, the Expert Panel 
of the American College of Radiology recommended CT 
scans as the most optimal method of controlling this 
group of patients during the first 5 years of follow-up. 
After 5 years’ surveillance, it is acceptable to perform a 
chest X-ray once per year.
In terms of local recurrence, the follow-up should 
include a careful H&P—especially of the region of the 
scar after primary site resection. Ultrasound examination 
of the limbs or trunk might be helpful in selected cases, 
which are not easily accessible to physical examination 
[12–14]. Patients should be informed about the role of 
self-examination of the site after STS resection, because 
most instances of local recurrence can be detected by 
self-examination. In Whooley et al.’s [10, 11] series, all 
but 1 of 29 local relapses were detected before imaging. 
Some experts recommend ultrasound or magnetic reso-
nance imaging (MRI) for early detection of local relapse 
in patients with high-grade STS or after non-radical sur-
gery. However, no consensus for the role of MRI in the 
follow-up of sarcoma patients [15, 16] has so far been 
established. During follow-up, it is important to dis-
tinguish local relapse from postoperative changes. In 
MRI scans, the recurrence pattern may be indicated by 
particularly significant signal intensity on T2-weighted 
and dynamic contrast-enhanced sequences. It is worth 
pointing out that the cost/benefit ratio does not justify 
the routine use of this type of imaging.
On the other hand, in retroperitoneal, intraperitoneal, 
or inguinal STS, effective follow-up is based on spiral 
contrast enhanced-CT or MRI. Clinical examination is 
difficult in these localizations [2, 17]. What is more, local 
recurrence of retroperitoneal or intraperitoneal STS is 
more frequent than in primary tumors localized in the 
limbs or subcutaneously. According to many experi-
enced surgeons, less frequent follow-up visits are justi-
fied in patients with a second relapse of retroperitoneal 
sarcomas, because there is no evidence that in these cases 
early detection of a relapse improves survival. It is impor-
tant to remember that it is mandatory to educate patients 
about self-examination. Self-examination enables local 
recurrence to be detected at scheduled visits.
Effective follow-up schedules in patients with 
STS
There are no universal recommendations for the follow-
up of sarcoma patients after multimodal treatment [2, 3, 
Table 1 Follow-up recommendation in soft tissue sarcoma
Recommendation Time-line
After radical treatment of 
sarcoma in stage IA-IB 
(low-grade/G1)
H&P (rule out local relapse!) every 3–6 months for 2–3 years; annually thereafter.
Consider baseline CT/MRI or ultrasound at 6 months after surgery.
In retroperitoneal and intraperitoneal sarcomas, abdominal/pelvic CT every 6 months (for the 
first 2–3 years), then once a year. In other cases, imaging studies only when clinically indicated.
Chest X-ray every 6–12 months, if metastatic nodules are suspected—perform chest CT.
Mandatory to educate patients about self-examination
Every 3–6 months for 2–3 
years; annually thereafter 
(more than 10 years of follow-
up after radiotherapy)
After radical treatment 
of sarcoma in stage II-III 
(G2/3) or after lymph node 
dissection
H&P (rule out local relapse!)
Ultrasound—optional, but no more than once a year. Consider baseline CT/MRI or ultrasound 
at 6 months after surgery. In retroperitoneal and intraperitoneal sarcomas, abdominal/pelvic CT 
every 6 months (for the first 2–3 years), then once a year. In other cases, imaging studies only 
when clinically indicated. Chest X-ray or chest CT every 3-6 months.
Mandatory to educate patient about self-examination
Every 3–6 months for 2–3 
years; then every 6–12 
months for 3 years; and annu-
ally thereafter
After treatment of disease 
dissemination (stage IV)
The assessment of metastatic (target) lesions on CT or MRI An individual plan of follow-up 
visits
CT computed tomography, MRI magnetic resonance imaging
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of positron emission tomography (PET) in STS is not well 
established.
GIST patients should be informed of the possibility 
of relapse even after a long period of observation [20, 
24]. After resection of low-risk GISTs, the probability of 
recurrence still exists, but hopefully its rate is signifi-
cantly lower than in the intermediate/high risk groups. 
Once-a-year controls in these patients are therefore sat-
isfactory [24, 25]. On the contrary, when there is high/
intermediate risk of relapse (if the patient did not qualify 
for adjuvant treatment), close monitoring should be car-
ried out by abdominal/pelvic CT. Assessment is required 
every 3–4 months for the first 2–3 years after resection, 
when the risk of relapse is highest, then every 6 months 
for the next 2–3 years; a follow-up once a year is satisfac-
tory thereafter [19, 20, 24, 26]. A similar follow-up sched-
ule is also recommended for patients receiving adjuvant 
treatment with imatinib after termination of adjuvant 
therapy. The risk of relapse is also increased in this group 
of patients (Table 2).
To objectively evaluate tumor response in patients 
with GIST undergoing treatment with imatinib, con-
trast-enhanced CT of the abdomen and pelvis is the 
best option (the contrast should be administered orally 
and intravenously). The first CT scan should be per-
formed a few days before the start of treatment, and 
then repeated every 2 months (6–8 weeks) during the 
first 6 months of therapy. After 6 months of therapy, 
response should be evaluated every 3–4 months. In 
some cases, clinical response after imatinib adminis-
tration appears to be slower (median time to response 
is 4 months). Therefore, the results of CT after 6–8 weeks 
of therapy must be assessed cautiously, and it is impor-
tant to reassess response in (at least) two consecutive 
CT scans. The most important factors in radiological 
response are changes in the size of the tumor accord-
ing to the Response Evaluation Criteria in Solid Tumors 
(RECIST). The sum of the longest diameter should be 
calculated and monitored for all target lesions. Pro-
gression is recognized when the sum of the diameters 
5, 17–20]. Although several schemes have been proposed 
[2, 3, 5, 17], only a few studies have been conducted on 
their utility [1, 4, 21–23]. Reference oncological centers 
recommend visits every 3–4 months for the first 2 (or 3) 
years of observation, and every 6 months for the follow-
ing 2 years (Table  1). Once-yearly visits are satisfactory 
thereafter. The risk of recurrence depends on histologi-
cal grade and subtype, size of the primary tumor (in cm), 
adequate surgery and time from initial sarcoma treat-
ment [2, 4, 5, 17]. It has been proven that after radical 
treatment, low-grade STSs (less than 5 cm in size) have 
a very small risk of relapse. Therefore, with an easily 
accessible site after a primary tumor, there is no need to 
perform any additional imaging studies, except for chest 
X-ray, to be performed every 6–12 months for the first 3 
years, and then once a year. Conversely, in high grade 
sarcomas, where the risk of metastases (to the lungs) and 
local recurrence is much higher, it is necessary to perform 
regular, careful physical examination, and chest imaging 
[4]. Routine evaluation of the regional lymph nodes is 
justified only in selected subtypes of STS, e.g., clear cell 
sarcoma, epithelioid sarcoma, rhabdomyosarcoma, and 
synovial sarcoma. It is very important to assess the abdo-
men in myxoid liposarcoma.
The only randomized trial evaluating the intensity and 
pattern of follow-up after surgery for extremity sarcomas 
[23] showed that inexpensive imaging with chest X-rays 
detected the majority of disease recurrences without 
deleterious effects on patient survival. It did not give a 
definitive answer about the recommended frequency 
of follow visits: 3-monthly versus 6-monthly intervals. 
Notably, almost 90 % of local recurrences were identified 
by patients based on self-examination.
Routine blood tests or other serum markers are not 
effective in the detection of disease dissemination or 
local recurrence [18]. If tumor localization is inaccessible 
to physical examination (retroperitoneal and intraperi-
toneal locations), then it is justified to perform imag-
ing for early detection of recurrent disease. The study of 
choice in these cases is contrast-enhanced CT. The role 
Table 2 Follow-up recommendation in GIST
Recommendation Time-line
After radical treatment of 
patients with low and very low 
risk GIST (stage I)
There is no indication for regular follow-up.
Ultrasound or abdominal/pelvic CT might be considered once a year.
The patient must be informed of risk of relapse even after a long period of 
treatment
Once a year
After radical treatment of 
patients with intermediate risk 
GIST (stage II)
H&P.
Abdominal/pelvic CT with contrast.
Imaging assessment depending on localization of primary tumor (e.g., 
pelvic MRI in a rectal GIST, chest CT in an esophageal GIST)
Every 3–6 months for 2–3 years; then every 
6–12 months for 3 years; and annually 
thereafter
After radical treatment of 
patients with high risk GIST 
(stage III)
H&P.
Abdominal/pelvic CT with contrast.
Imaging assessment depending on localization of primary tumor (e.g., 
pelvic MRI in a rectal GIST, chest CT in an esophageal GIST)
Every 3–4 months for 2–3 years; then every 
6 months for the next 3 years; and annually 
thereafter (after adjuvant imatinib, follow-up 
starts after the end of systemic treatment)
After radical treatment of 
metastatic GIST (stage IV)
The assessment of metastatic (target) lesions on abdominal/pelvic CT or 
MRI
An individual plan of follow-up visits—during 
the TKI therapy, follow-up is recommended 
every 2–3 months
CT computed tomography, MRI magnetic resonance imaging, GIST gastrointestinal stromal tumor
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increases above 20 %. In GIST, response is also deter-
mined by assessing changes in tumor density (Choi 
criteria) [19, 20, 25]. Second-line treatment with other 
tyrosine kinase inhibitors requires similar follow-up 
(CT every 2–3 months).
In STS follow-up, it is important to educate patients 
about self-examination and the possibility of late 
relapse (even after 10 years from the initial diagnosis). 
It is crucial to monitor late side effects of multimodal 
treatment in patients, specifically due to the risk of 
secondary neoplasms induced by radiotherapy and/or 
chemotherapy.
Summary
The majority (over 95 %) of STS relapses occur within 5 
years after treatment. Moreover, 80 % of metastases to the 
lung and close to 70 % of local recurrences occur within 
the first 2–3 years of follow-up. Along with advances 
in the treatment of sarcomas, earlier detection of less 
advanced, resectable, recurrent diseases (local or meta-
static—especially to the lungs) can prolong patient sur-
vival. Follow-up strategy is based on three elements: 
efficient, unsophisticated methods of observation after 
therapy which are cost effective and must be carried out 
precisely [27]. Hence, in the period between 2 and 3 years 
after treatment, it is mandatory to follow-up patients 
every 3 months and perform careful H&P (especially 
scars after surgery of the primary site) and chest X-ray. 
There is no reason to perform other studies in asymp-
tomatic patients (unless the patient reports symptoms). 
In case of retroperitoneal or intraperitoneal STS (includ-
ing GISTs), contrast-enhanced computed tomography of 
the abdomen and pelvis is recommended as the follow-
up modality of choice.
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